78238-14-9

Usage

Uses

Used in Pharmaceutical Industry:
3-Hydroxy-5-nitrobenzoic acid is used as an intermediate in the synthesis of pharmaceuticals for its versatile chemical properties. Its ability to form various derivatives makes it a valuable component in the development of new drugs.
Used in Dye and Pigment Industry:
In the dye and pigment industry, 3-Hydroxy-5-nitrobenzoic acid is utilized as an intermediate to produce a range of dyes and pigments. Its chemical structure allows for the creation of colorants with specific properties, such as color intensity and stability.
Used in Medicinal Chemistry Research:
3-Hydroxy-5-nitrobenzoic acid is used as a subject of interest in medicinal chemistry research due to its potential antimicrobial and anti-inflammatory properties. Scientists are investigating its ability to inhibit the growth of certain microorganisms and reduce inflammation, which could lead to the development of new treatments for various diseases and conditions.

InChI:InChI=1/C7H5NO5/c9-6-2-4(7(10)11)1-5(3-6)8(12)13/h1-3,9H,(H,10,11)

Upstream product

• 618-84-8 3-amino-5-nitro-benzoic acid 
• 78238-13-8 3-methoxy-5-nitrobenzoic acid methyl ester 
• 78238-12-7 3-methoxy-5-nitrobenzoic acid 
• 99-34-3 3,5-dinitrobenzoic acid 
• 2702-58-1 methyl 3,5-dinitrobenzoate 
• 65-85-0 benzoic acid 

Downstream Products

• 55076-32-9 methyl 3-hydroxy-5-nitrobenzoate 
• 76045-71-1 3-amino-5-hydroxybenzoic acid 
• 14206-69-0 3-amino-5-hydroxybenzoic acid hydrochloride 
• 180628-74-4 3-hydroxy-5-nitrobenzyl alcohol 
• 78238-13-8 3-methoxy-5-nitrobenzoic acid methyl ester 
• 92010-04-3 methyl α-(tert-butoxycarbonyl)-5-propionamido-m-anisate 
• 92010-09-8 5-(p-chlorobenzamido)-α-carboxy-m-anisic acid 
• 92010-13-4 5-(p-bromobenzamido)-α-carboxy-m-anisic acid 
• 92010-02-1 methyl α-(tert-butoxycarbonyl)-5-benzamido-m-anisate 
• 92010-06-5 methyl α-(tert-butoxycarbonyl)-5-octanamido-m-anisate 
• 92010-11-2 5-(3,4-dichlorobenzamido)-α-carboxy-m-anisic acid 
• 92010-08-7 methyl α-(tert-butoxycarbonyl)-5-(p-chlorobenzamido)-m-anisate 
• 92010-12-3 methyl α-(tert-butoxycarbonyl)-5-(p-bromobenzamido)-m-anisate 
• 92010-10-1 methyl α-(tert-butoxycarbonyl)-5-(3,4-dichlorobenzamido)-m-anisate 

Relevant academic research and scientific papers

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

METHOD FOR SPECIFIC CLEAVAGE OF C Alpha-C BOND AND SIDE CHAIN OF PROTEIN AND PEPTIDE, AND METHOD FOR DETERMINING AMINO ACID SEQUENCE

The present invention provides a method for specifically cleaving a Cα-C bond of a peptide backbone and/or a side chain of a protein and a peptide, and a method for determining amino acid sequences of protein and peptide. A method for specifically cleaving a Cα-C bond of a peptide backbone and/or a side chain bond of a protein or a peptide, comprising irradiating a protein or a peptide with laser light in the presence of at least one hydroxynitrobenzoic acid selected from the group consisting of 3-hydroxy-2-nitrobenzoic acid, 4-hydroxy-3-nitrobenzoic acid, 5-hydroxy-2-nitrobenzoic acid, 3-hydroxy-5-nitrobenzoic acid, and 4-hydroxy-2-nitrobenzoic acid. A method for determining an amino acid sequence of a protein or a peptide, comprising irradiating a protein or a peptide with laser light in the presence of the above specific hydroxynitrobenzoic acid to specifically cleave a Cα-C bond of a peptide backbone and/or a side chain bond, and analyzing generated fragment ions by mass spectrometry.

Synthesis of an Advanced Fragment of (+)-Trienomycinol

The synthesis of the fully functionalized eastern fragment of trienomycins A-F, ansamycin antibiotics is described. A key step involves a peptidic coupling between a sulfonyl aniline and an enantiopure carboxylic acid obtained by a completely diastereosel

Halide-guided oligo(aryl-triazole-amide)s foldamers: Receptors for multiple halide ions

We synthesized and characterized a series of oligo(phenyl-amide-triazole)s that can fold into a helical conformation guided by halide ions. Their binding models and affinities are highly dependent on the length of the foldamer, media and the inducing capa

NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

The present invention relates to a novel tricyclic derivative with efficient inhibitory activity against poly(ADP-ribose)polymerases (PARP) or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition containing the same. The tricyclic derivative of the invention is useful for the prevention or treatment of diseases caused by excess PARP activity, especially neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic nephropathy, inflammatory diseases, osteoporosis, and cancer, by inhibiting the activity of poly(ADP-ribose)polymerases.

NOVEL TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

The present invention relates to a novel tricyclic derivative with efficient inhibitory activity against poly(ADP-ribose)polymerases (PARP) or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition containing the same. The tricyclic derivative of the invention is useful for the prevention or treatment of diseases caused by excess PARP activity, especially neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic nephropathy, inflammatory diseases, osteoporosis, and cancer, by inhibiting the activity of poly(ADP-ribose)polymerases.

Synthesis of potential early-stage intermediates in the biosynthesis of FR900482 and mitomycin c

Beyond the identification of 3-amino-5-hydroxybenzoic acid (AHBA) and D-glucosamine as biosynthetic precursors to mitomycin C (5) and FR900482 (6), little is known about the pathway Nature uses to prepare these antitumor antibiotics. To gain some insight

Stereochemical assignment of intermediates in the rifamycin biosynthetic pathway by precursor-directed biosynthesis

Natural and semisynthetic rifamycins are clinically important inhibitors of bacterial DNA-dependent RNA polymerase. Although the polyketide-nonribosomal peptide origin of the naphthalene core of rifamycin B is well established, the absolute and relative c

Heterogeneous foldamers containing alpha, beta, and/or gamma-amino acids

Disclosed are isolated, unnatural polypeptides containing cyclically-constrained β-amino acid residues and cyclically-constrained γ-amino acid residues. The compounds are unnatural and because they contain rotationally constrained residues that are not amenable to enzymatic degradation, the compounds are useful to probe protein-protein and other large molecule interactions.

Design, synthesis, and testing of potential antisickling agents. 5. Disubstituted benzoic acids designed for the donor site and proline salicylates designed for the acceptor site

This paper reports the discovery of a new class of potent antigelling agents. The new compounds, disubstituted benzoic acid derivatives, were designed by using molecular modeling experiments. These molecules contain functional groups positioned to interac